Literature DB >> 21377338

Brain magnetic resonance spectroscopy in obsessive-compulsive disorder: the importance of considering subclinical symptoms of anxiety and depression.

Marie-Josée Bédard1, Sophie Chantal.   

Abstract

Brain metabolite concentrations have recently been assessed in different cerebral regions presumably targeted in patients with obsessive-compulsive disorder (OCD) using magnetic resonance spectroscopy (MRS). However, results have been divergent. Possible confounding variables, such as the cerebral localisation of investigated regions and metabolites considered, as well as subclinical symptoms of anxiety and depression, could have affected these MRS profiles. The main goal of this study was to assess MRS metabolite differences between 13 individuals with OCD and 12 matched healthy controls in seven brain regions potentially involved in OCD. The secondary objective was to assess the relationships between levels of anxiety and depression and brain metabolite concentrations. No difference was found for N-acetylaspartate, glutamate-glutamine, myo-inositol (mI) and choline relative to creatine (Cr) concentration in either the left or right orbitofrontal area, left or right median temporal lobe, left or right thalamus or the anterior cingulate cortex. A significant negative correlation between the mI/Cr in the left orbitofrontal area and the severity of OCD symptomatology was observed while subclinical anxiety and depression were closely related to brain metabolite ratios. Thus, these subclinical symptoms, commonly associated with OCD, should be considered in assessing brain metabolite concentrations and may be central to the comprehension of this disorder.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21377338     DOI: 10.1016/j.pscychresns.2010.10.008

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder.

Authors:  Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

2.  Neurochemicals measured by (1)H-MR spectroscopy: putative vulnerability biomarkers for obsessive compulsive disorder.

Authors:  Sundar Gnanavel; Pratap Sharan; Sudhir Khandelwal; Uma Sharma; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2013-12-12       Impact factor: 2.310

Review 3.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

4.  Magnetic Resonance Spectroscopy (MRS) and Positron Emission Tomography (PET) Imaging in Obsessive-Compulsive Disorder.

Authors:  Marjan Biria; Lucia-Manuela Cantonas; Paula Banca
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 5.  A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder.

Authors:  Brian P Brennan; Scott L Rauch; J Eric Jensen; Harrison G Pope
Journal:  Biol Psychiatry       Date:  2012-07-24       Impact factor: 13.382

6.  Cingulate and thalamic metabolites in obsessive-compulsive disorder.

Authors:  Joseph O'Neill; Tsz M Lai; Courtney Sheen; Giulia C Salgari; Ronald Ly; Casey Armstrong; Susanna Chang; Jennifer G Levitt; Noriko Salamon; Jeffry R Alger; Jamie D Feusner
Journal:  Psychiatry Res Neuroimaging       Date:  2016-05-24       Impact factor: 2.376

7.  Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive-compulsive disorder: meta-analyses of (1)H-MRS studies.

Authors:  Yuta Aoki; Ai Aoki; Hiroshi Suwa
Journal:  Transl Psychiatry       Date:  2012-08-14       Impact factor: 6.222

Review 8.  Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.

Authors:  Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.